Status:
UNKNOWN
Topical Tacrolimus 0.03% Ointment for Intractable Allergic Conjunctivitis: An Open Label Pilot Study
Lead Sponsor:
Assaf-Harofeh Medical Center
Conditions:
Allergic Conjunctivitis
Eligibility:
All Genders
5+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the efficacy, tolerance and safety of tacrolimus 0.03% ointment in the treatment of intractable allergic conjunctivitis.
Eligibility Criteria
Inclusion
- Subjects included if they were \> 5 years old and suffered from intractable allergic conjunctivitis
Exclusion
- pregnancy or breastfeeding,history of herpetic eye disease,transplant patients concomitant administration of drugs inhibiting cytochrome CYP3A4, hypersensitivity to macrolides
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00443105
Last Update
March 5 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assaf Harofeh Medical Center, Department of Ophthalmology
Ẕerifin, Israel, 70300